Representative before the EPO

Company dna sma solar technology ag
no operation time available
2 offices
active in Legal Services

Representative before the EPO

Employment test 1001 - 5000 employees
Company dna gowling lafleur henderson llp
operating since 1887
Headquarter in Toronto and 9 offices
active in Legal Services, IP Consulting, Matchmaking and Trading, and IP Portfolio Processing

Representative before the EPO

Technology company logo thumb
no operation time available
4 offices
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
4 offices
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
3 offices
Technology Company

We have observed 9 EP applications Sean Matthew Alexander has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after June 20, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP13762842

SALMONID ALPHAVIRUS AND USES THEREOF

IPC classification:
A61K 39/12, G01N 33/569, C07K 14/18
Applicant:
Novartis Tiergesundheit AG
Agent:
Sean Matthew Alexander, Eli Lilly and Company Limited
Agent:
David Richard Spinner, Greaves Brewster LLP
Status:
PATENT GRANTED
EP13789453

FLAVIVIRUS ASSOCIATED WITH THEILER'S DISEASE

IPC classification:
C12Q 1/68, C07K 14/005
Applicant:
Center for Technology Licensing (CTL) at Cornell University
Applicant:
Novartis Tiergesundheit AG
Applicant:
Cornell University
Agent:
Sean Matthew Alexander, Eli Lilly and Company Limited
Agent:
David Richard Spinner, Greaves Brewster LLP
Status:
The patent has been granted
EP14726176

INTERACTIONS OF BETANODAVIRUSES IN INFECTION

IPC classification:
A61K 39/12
Applicant:
University of Málaga (Universidad de Malaga)
Applicant:
Novartis Tiergesundheit AG
Agent:
Sean Matthew Alexander, Eli Lilly and Company Limited
Agent:
David Richard Spinner, Greaves Brewster LLP
Status:
GRANT OF PATENT INTENDED
EP14748051

METHODS FOR PREPARING INACTIVATED ROTAVIRUS

IPC classification:
C12N 7/00, A61K 39/12
Applicant:
Novartis Tiergesundheit AG
Agent:
Sean Matthew Alexander, Eli Lilly and Company Limited
Agent:
David Richard Spinner, Greaves Brewster LLP
Status:
EXAMINATION IN PROGRESS
EP15713431

NEW COMPOUNDS

IPC classification:
A61K 31/52, A61K 31/505, A61K 31/50, A61K 31/44, C07D 495/04, C07D 487/04, C07D 473/34, C07D 471/14, C07D 471/04, C07D 239/46
Applicant:
Novartis Tiergesundheit AG
Agent:
Sean Matthew Alexander, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP17161398

MODIFIED ANIMAL ERYTHROPOIETIN POLYPEPTIDES AND THEIR USES

IPC classification:
A61P 7/06, C12P 21/02, C12N 5/10, C12N 15/16, C12N 15/11, C07K 14/505
Agent:
Sean Matthew Alexander, Eli Lilly and Company Limited
Status:
The application has been published
EP17161531

MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES

IPC classification:
A61K 38/00
Agent:
Sean Matthew Alexander, Eli Lilly and Company Limited
Status:
The application has been published
EP15805062

METHODS FOR TREATING KIDNEY DISORDERS

IPC classification:
A61P 13/12, A61K 31/422
Applicant:
Eli Lilly and Company Limited
Agent:
Sean Matthew Alexander, Eli Lilly and Company Limited
Status:
Request for examination was made
EP17199031

NEW COMBINATION

IPC classification:
A61K 47/12, A61K 31/501, A61K 31/4184, A61K 9/20
Agent:
Sean Matthew Alexander, Eli Lilly and Company Limited
Status:
The application has been published

Please Sign in to use this feature